Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees.
Related news for (ONCT)
- oncternal therapeutics announces updated safety and efficacy data for phase 1/2 study of onct-534 for the treatment of r/r metastatic castration-resistant prostate cancer
- Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
- Oncternal Therapeutics Announces Reverse Stock Split